<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624036</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-108</org_study_id>
    <secondary_id>2018-001923-38</secondary_id>
    <nct_id>NCT03624036</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma</brief_title>
  <acronym>ZUMA-8</acronym>
  <official_title>A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of&#xD;
      brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic&#xD;
      leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Actual">February 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicity (DLTs) in participants treated with brexucabtagene autoleucel (KTE-X19)</measure>
    <time_frame>Within first 28 days following infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per Investigator Review</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Objective response rate is defined per the IWCLL 2018 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Anti-CD19 CAR T-Cells in Blood</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>brexucabtagene autoleucel (KTE-X19)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive conditioning chemotherapy (fludarabine and cyclophosphamide), followed by the investigational treatment, brexucabtagene autoleucel (KTE-X19).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>brexucabtagene autoleucel (KTE-X19)</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously</description>
    <arm_group_label>brexucabtagene autoleucel (KTE-X19)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>brexucabtagene autoleucel (KTE-X19)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>brexucabtagene autoleucel (KTE-X19)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Documentation of relapsed or refractory CLL and SLL; must have received at least 2&#xD;
             prior lines of treatment, one of which must include a Bruton's tyrosine kinase (BTK)&#xD;
             inhibitor.&#xD;
&#xD;
               -  Cohort 1 and 2: Subjects with r/r CLL who have received at least 2 prior lines of&#xD;
                  treatment, one of which must include a BTK inhibitor.&#xD;
&#xD;
               -  Cohort 3: Subjects with r/r CLL and SLL must present with ≤ 1% circulating tumor&#xD;
                  cells in peripheral blood or ALC &lt; 5000 cells/μL. Subjects must have received at&#xD;
                  least 2 prior lines of treatment, one of which must include a BTK inhibitor.&#xD;
&#xD;
               -  Cohort 4: Subjects with r/r CLL who have received at least 2 prior lines of&#xD;
                  treatment and must have received ibrutinib as a single agent or in comibation&#xD;
                  with anti-CD20 antibodies, BCL-2 inhibitors, and PI3k inhibitors for at least 6&#xD;
                  months as the last line of therapy prior to screening. Ibrutinib administration&#xD;
                  will continue up to 30 hours prior to leukapheresis. In case of treatment&#xD;
                  interruption with ibrutinib, the principal investigator should reach out to the&#xD;
                  medical monitor to discuss.&#xD;
&#xD;
          -  An indication for treatment per IWCLL 2018 criteria and radiographically measurable&#xD;
             disease (at least 1 lesion &gt; 1.5 cm in diameter)&#xD;
&#xD;
          -  Adequate hematologic function as indicated by:&#xD;
&#xD;
               -  Platelet count ≥ 50 × 10^9/L&#xD;
&#xD;
               -  Neutrophil count ≥ 0.5 × 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL unless lower values are attributable to CLL&#xD;
&#xD;
          -  Adequate renal, hepatic, cardiac and pulmonary function defined as:&#xD;
&#xD;
               -  Creatinine clearance (as estimated by Cockcroft-Gault) ≥ 60 mL/min&#xD;
&#xD;
               -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 x&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 mg/dL unless subject has Gilbert's syndrome&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) ≥ 50%, no evidence of pericardial&#xD;
                  effusion, no New York Heart Association (NYHA) class III or IV functional&#xD;
                  classification, no clinically significant arrhythmias&#xD;
&#xD;
               -  No clinically significant pleural effusion&#xD;
&#xD;
               -  Baseline oxygen saturation &gt; 92% on room air&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any&#xD;
             prior systemic therapy or BTKi (ibrutinib or acalabrutinib) at the time the subject is&#xD;
             planned for leukapheresis, except for systemic inhibitory/stimulatory immune&#xD;
             checkpoint therapy. At least 3 half-lives must have elapsed from any prior systemic&#xD;
             inhibitory/stimulatory immune checkpoint molecule therapy at the time the subject is&#xD;
             planned for leukapheresis (eg, ipilimumab, nivolumab, pembrolizumab, atezolizumab,&#xD;
             OX40 agonists, 4-1BB agonists)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  A history of treatment including any of the following:&#xD;
&#xD;
               -  Prior CD19 directed therapy&#xD;
&#xD;
               -  Prior allogeneic hematopoietic stem cell transplant (SCT) or donor lymphocyte&#xD;
                  infusion (DLI) within 6 months prior to enrollment&#xD;
&#xD;
          -  History of autoimmune disease resulting in end-organ injury unless attributable to CLL&#xD;
             (eg, idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA))&#xD;
&#xD;
          -  Diagnosis of Richter's transformation or a history of malignancy other than&#xD;
             non-melanoma skin cancer or carcinoma in situ (eg, skin, cervix, bladder, breast),&#xD;
             superficial bladder cancer, asymptomatic localized low grade prostate cancer for which&#xD;
             watch-and-wait approach is standard of care, or any other cancer that has been in&#xD;
             remission for &gt; 3 years prior to enrollment&#xD;
&#xD;
          -  History of severe hypersensitivity reaction attributed to aminoglycosides&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Cancer Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

